
William Alazawi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4258984/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The contribution of daytime sleepiness to impaired quality of life in NAFLD in an ethnically diverse population. Scientific Reports, 2022, 12, 5123.	1.6	2
2	Association of gamma-glutamyltransferase levels with total mortality, liver-related and cardiovascular outcomes: A prospective cohort study in the UK Biobank. EClinicalMedicine, 2022, 48, 101435.	3.2	11
3	What's new in non-alcoholic fatty liver disease?. Frontline Gastroenterology, 2022, 13, e102-e108.	0.9	9
4	Myeloid XBP1 links lipid overload with inflammation in NASH: Do advances in basic science have clinical potential?. Journal of Hepatology, 2022, 77, 290-292.	1.8	0
5	Socioeconomic Factors Associated With Liver-Related Mortality From 1985 to 2015 in 36 Developed Countries. Clinical Gastroenterology and Hepatology, 2021, 19, 1698-1707.e13.	2.4	10
6	Obesity Predicts Liver Function Testing and Abnormal Liver Results. Obesity, 2020, 28, 132-138.	1.5	5
7	Serious complications due to study-mandated liver biopsies in phase 3 trials for patients with advanced fibrosis due to non-alcoholic steatohepatitis. Journal of Hepatology, 2020, 73, S164.	1.8	Ο
8	Improvements in the ELF test are associated with widespread changes in the hepatic transcriptome in patients with advanced fibrosis due to non-alcoholic steatohepatitis. Journal of Hepatology, 2020, 73, S528-S530.	1.8	0
9	Stat2 loss disrupts damage signalling and is protective in acute pancreatitis. Journal of Pathology, 2020, 252, 41-52.	2.1	3
10	Improving prevention strategies for cardiometabolic disease. Nature Medicine, 2020, 26, 320-325.	15.2	71
11	Non-alcoholic fatty liver disease. Clinical Medicine, 2020, 20, 509-512.	0.8	11
12	ADAM17-Mediated Reduction in CD14++CD16+ Monocytes ex vivo and Reduction in Intermediate Monocytes With Immune Paresis in Acute Pancreatitis and Acute Alcoholic Hepatitis. Frontiers in Immunology, 2019, 10, 1902.	2.2	11
13	Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Medicine, 2019, 17, 95.	2.3	192
14	Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ: British Medical Journal, 2019, 367, l5367.	2.4	175
15	Nonâ€alcoholic fatty liver disease in men. Trends in Urology & Men's Health, 2019, 10, 6-9.	0.2	Ο
16	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 394, 2184-2196.	6.3	818
17	Authors' reply to McKenna-Barry and Ryan. BMJ, The, 2019, 367, l6549.	3.0	0
18	Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials. American Journal of Physiology - Renal Physiology, 2019, 316, G372-G386.	1.6	5

WILLIAM ALAZAWI

#	Article	IF	CITATIONS
19	Genetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy?. Frontiers in Pharmacology, 2019, 10, 1413.	1.6	17
20	Interfering with Kupffer cell replenishment: New insights into liver injury. Journal of Hepatology, 2018, 68, 635-637.	1.8	11
21	Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent. Frontline Gastroenterology, 2018, 9, 115-121.	0.9	23
22	Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Medicine, 2018, 16, 130.	2.3	177
23	Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. Frontline Gastroenterology, 2017, 8, 252-259.	0.9	22
24	Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease. American Journal of the Medical Sciences, 2017, 354, 172-181.	0.4	56
25	Periodontitis is associated with significant hepatic fibrosis in patients with non-alcoholic fatty liver disease. PLoS ONE, 2017, 12, e0185902.	1.1	54
26	Systemic Inflammatory Response Syndrome After Major Abdominal Surgery Predicted by Early Upregulation of TLR4 and TLR5. Annals of Surgery, 2016, 263, 1028-1037.	2.1	41
27	Inflammatory and Immune Responses to Surgery and Their Clinical Impact. Annals of Surgery, 2016, 264, 73-80.	2.1	190
28	Practical approach to nonâ€alcoholic fatty liver disease in patients with diabetes. Diabetic Medicine, 2015, 32, 1121-1133.	1.2	15
29	Research into practice: understanding ethnic differences in healthcare usage and outcomes in general practice. British Journal of General Practice, 2014, 64, 653-655.	0.7	12
30	Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nature Medicine, 2014, 20, 518-523.	15.2	240
31	Ethnicity and the diagnosis gap in liver disease: a population-based study. British Journal of General Practice, 2014, 64, e694-e702.	0.7	39
32	Maintaining clinical governance when giving telephone advice. Frontline Gastroenterology, 2013, 4, 270-277.	0.9	0
33	A cross sectional study of colonic diverticulosis in the London Bangladeshi population. United European Gastroenterology Journal, 2013, 1, 191-197.	1.6	8
34	Stat2 loss leads to cytokine-independent, cell-mediated lethality in LPS-induced sepsis. Proceedings of the United States of America, 2013, 110, 8656-8661.	3.3	35
35	Endothelinâ€1 as a Mediator and Potential Biomarker for Interferon Induced Pulmonary Toxicity. Pulmonary Circulation, 2012, 2, 501-504.	0.8	19
36	Pharmacology and therapeutic potential of interferons. , 2012, 135, 44-53.		143

3

#	Article	IF	CITATIONS
37	Benefits of knowledge-based interprofessional communication skills training in medical undergraduate education. JRSM Short Reports, 2011, 2, 1-8.	0.6	6
38	Advances in the diagnosis and treatment of hepatitis B. Current Opinion in Infectious Diseases, 2008, 21, 508-515.	1.3	12
39	Changes in cervical keratinocyte gene expression associated with integration of human papillomavirus 16. Cancer Research, 2002, 62, 6959-65.	0.4	77